NasdaqGS - Delayed Quote • USD
Metagenomi, Inc. (MGX)
At close: 4:00 PM EDT
After hours: 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.65 | -0.81 | -3.35 | -3.42 |
| Low Estimate | -0.87 | -0.9 | -3.98 | -4.12 |
| High Estimate | -0.31 | -0.71 | -2.9 | -2.62 |
| Year Ago EPS | -- | -- | -20.05 | -3.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 5 |
| Avg. Estimate | 13.98M | 7.9M | 39.26M | 26.36M |
| Low Estimate | 7M | 1.5M | 30M | 10M |
| High Estimate | 26M | 11M | 58M | 44M |
| Year Ago Sales | -- | -- | 44.76M | 39.26M |
| Sales Growth (year/est) | -- | -- | -12.30% | -32.90% |
Earnings History
| CURRENCY IN USD | 3/31/2024 | |||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -0.78 |
| EPS Actual | -- | -- | -- | -1.19 |
| Difference | -- | -- | -- | -0.41 |
| Surprise % | -- | -- | -- | -52.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.65 | -0.81 | -3.35 | -3.42 |
| 7 Days Ago | -0.6 | -0.8 | -3.2 | -3.12 |
| 30 Days Ago | -0.69 | -0.73 | -2.96 | -2.94 |
| 60 Days Ago | -0.71 | -0.75 | -3.02 | -2.81 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 3 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MGX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 7.90% |
| Next Qtr. | -- | -- | -- | 10.20% |
| Current Year | 83.30% | -- | -- | 4.80% |
| Next Year | -2.10% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Initiated | HC Wainwright & Co.: Buy | 5/7/2024 |
| Downgrade | JP Morgan: Overweight to Neutral | 5/2/2024 |
| Maintains | Chardan Capital: Buy to Buy | 3/28/2024 |
| Initiated | TD Cowen: Outperform | 3/5/2024 |
| Initiated | Wells Fargo: Overweight | 3/5/2024 |
Related Tickers
KYTX Kyverna Therapeutics, Inc.
13.23
+1.77%
ANRO Alto Neuroscience, Inc.
12.28
-4.95%
AVBP ArriVent BioPharma, Inc.
18.97
-1.40%
GUTS Fractyl Health, Inc.
6.57
-11.93%
CNTA Centessa Pharmaceuticals plc
8.10
-2.06%
NMRA Neumora Therapeutics, Inc.
9.51
+3.71%
NKTX Nkarta, Inc.
6.47
+0.47%
CGON CG Oncology, Inc.
32.43
-0.86%
HOWL Werewolf Therapeutics, Inc.
4.9600
+1.64%
HLVX HilleVax, Inc.
12.67
-1.71%